Refractory Cardiac Arrest Treated On Field By ECMO

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Apr 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special emergency treatment called ECMO (extracorporeal membrane oxygenation) for people who have had a cardiac arrest outside of a hospital and haven’t responded to standard resuscitation efforts. When someone suffers a cardiac arrest, their heart stops beating, and they need immediate help to get blood flowing again. In some cases, even after advanced medical care, the heart may not start beating again on its own. In these situations, the ECMO team in Paris can step in to provide this life-saving treatment. They use a machine that takes over the heart's job, helping to pump oxygenated blood to the body while waiting for the heart to recover.

To be a part of this trial, participants need to be adults who have received ECMO treatment following a cardiac arrest that wasn’t caused by an injury. The study is open to anyone aged 65 and older, and it is important that the patient or a family member agrees to participate, especially if the patient cannot give consent due to their health condition. Throughout the trial, participants or their families can expect to provide feedback on the treatment's effectiveness and their experience. This research aims to improve understanding of how well ECMO works in real-life situations and whether it can help save more lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients who have benefited from an installation or attempted installation of an extracorporeal membrane oxygenation (ECMO) device following a non-traumatic refractory cardiac arrest as part of the ECMO TEAM of the Samu de Paris during the time of the study.
• • Obtaining non-opposition from the patient or a relative in the event of the patient's death or a lasting state of health preventing them from becoming aware of the study.
• Exclusion Criteria:
• • - Minor patients